Down-regulated expression of hsa-miR-181c in Fanconi anemia patients: Implications in TNFα regulation and proliferation of hematopoietic progenitor cells

Blood

Volumn 119, Issue 13, 2012, Pages 3042-3049

  Río, Paula ^a   Agirre, Xabier ^b   Garate, Leire ^b   Baños, Rocío ^a   Álvarez, Lara ^a   San José Enériz, Edurne ^b   Badell, Isabel ^c   Casado, José A ^a   Garín, Marina ^a   Prósper, Felipe ^b   Bueren, Juan A ^a  

^a CIEMAT   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HSA MICRORNA 133A; HSA MICRORNA 135B; HSA MICRORNA 181C; LUCIFERASE; MICRORNA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ARTICLE; CELL COUNT; CELL PROLIFERATION; CLONOGENESIS; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ERYTHROID CELL; FANCONI ANEMIA; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MYELOID PROGENITOR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN RNA BINDING;

EID: 84859177105     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-01-331017     Document Type: Article

References (53)

1. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 2010;466(7308):835- 840.
2. Shivdasani RA. MicroRNAs: regulators of gene expression and cell differentiation. Blood. 2006;108(12):3646-3653. (Pubitemid 44864540)
3. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science. 2004;303(5654):83-86. (Pubitemid 38055775)
4. Georgantas RW, 3rd Hildreth R, Morisot S, et al. CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. Proc Natl Acad Sci U S A. 2007;104(8):2750-2755. (Pubitemid 46327951)
5. O'Connell RM, Chaudhuri AA, Rao DS, Gibson WS, Balazs AB, Baltimore D. MicroRNAs enriched in hematopoietic stem cells differentially regulate long-term hematopoietic output. Proc Natl Acad Sci U S A. 2010;107(32):14235-14240.
6. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99(24):15524-15529. (Pubitemid 35403967)
7. Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A. 2006; 103(18):7024-7029.
8. O'Connell RM, Rao DS, Chaudhuri AA, et al. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. J Exp Med. 2008;205(3):585-594. (Pubitemid 351439306)
9. Han YC, Park CY, Bhagat G, et al. microRNA-29a induces aberrant self-renewal capacity in hematopoietic progenitors, biased myeloid development, and acute myeloid leukemia. J Exp Med. 2010;207(3):475-489.
10. Kutler DI, Singh B, Satagopan J, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101(4):1249-1256. (Pubitemid 36182492)
11. Rosenberg PS, Greene MH, Alter BP. Cancer incidence in persons with Fanconi anemia. Blood. 2003;101(3):822-826. (Pubitemid 36139345)
12. Moldovan GL, D'Andrea AD. How the Fanconi Anemia Pathway Guards the Genome. Annu Rev Genet. 2009;43:223-249.
13. Garcia-Higuera I, Taniguchi T, Ganesan S, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell. 2001;7(2):249-262. (Pubitemid 32206493)
14. Smogorzewska A, Matsuoka S, Vinciguerra P, et al. Identification of the FANCI protein, a monoubiquitinated FANCD2 paralog required for DNA repair. Cell. 2007;129(2):289-301. (Pubitemid 46584733)
15. Niedernhofer LJ, Lalai AS, Hoeijmakers JH. Fanconi anemia (cross)linked to DNA repair. Cell. 2005;123(7):1191-1198. (Pubitemid 41821778)
16. Kratz K, Schopf B, Kaden S, et al. Deficiency of FANCD2-associated nuclease KIAA1018/FAN1 sensitizes cells to interstrand crosslinking agents. Cell. 2010;142(1):77-88.
17. MacKay C, Declais AC, Lundin C, et al. Identification of KIAA1018/FAN1, a DNA repair nuclease recruited to DNA damage by monoubiquitinated FANCD2. Cell. 2010;142(1):65-76.
18. Smogorzewska A, Desetty R, Saito TT, et al. A genetic screen identifies FAN1, a Fanconi anemia-associated nuclease necessary for DNA interstrand crosslink repair. Mol Cell. 2010;39(1):36-47.
19. Liu T, Ghosal G, Yuan J, Chen J, Huang J. FAN1 acts with FANCI-FANCD2 to promote DNA interstrand cross-link repair. Science. 2010;329(5992):693-696.
20. Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, Smogorzewska A. Mutations of the SLX4 gene in Fanconi anemia. Nat Genet. 2011;43(2):142-146.
21. Stoepker C, Hain K, Schuster B, et al. SLX4, a coordinator of structure-specific endonucleases, is mutated in a new Fanconi anemia subtype. Nat Genet. 2011;43(2):138-141.
22. Cybulski KE, Howlett NG. FANCP/SLX4: A Swiss Army knife of DNA interstrand crosslink repair. Cell Cycle. 2011;10(11):1757-1763.
23. Auerbach AD. Fanconi anemia diagnosis and the diepoxybutane (DEB) test. Exp Hematol. 1993;21(6):731-733. (Pubitemid 24215323)
24. Jacome A, Navarro S, Rio P, et al. Lentiviral-mediated genetic correction of hematopoietic and mesenchymal progenitor cells from Fanconi anemia patients. Mol Ther. 2009;17(6):1083-1092.
25. Bandrés E, Cubedo E, Agirre X, et al. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer. 2006;5:29.
26. Vilas-Zornoza A, Agirre X, Martin-Palanco V, et al. Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute lymphoblastic leukemia. PLoS One. 2011;6(2):e17012.
27. Dull T, Zufferey R, Kelly M, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72(11):8463-8471. (Pubitemid 28471781)
28. Dufour C, Corcione A, Svahn J, et al. TNF-alpha and IFN-gamma are overexpressed in the bone marrow of Fanconi anemia patients and TNF-alpha suppresses erythropoiesis in vitro. Blood. 2003;102(6):2053-2059. (Pubitemid 37122379)
29. Lamana B, Albella B, Rodríguez F, et al. Conclusions of a national multicentric intercomparative study of in vitro cultures of human hematopoietic progenitors. Bone Marrow Transplant. 1999;23(4):373-380. (Pubitemid 29105961)
30. Hashimoto Y, Akiyama Y, Otsubo T, Shimada S, Yuasa Y. Involvement of epigenetically silenced microRNA-181c in gastric carcinogenesis. Carcinogenesis. 2010;31(5):777-784.
31. Briot D, Mace-Aime G, Subra F, Rosselli F. Aberrant activation of stress-response pathways leads to TNF-alpha oversecretion in Fanconi anemia. Blood. 2008;111(4):1913-1923. (Pubitemid 351451500)
32. Ibáñez A, Rio P, Casado JA, Bueren JA, Fernandez-Luna JL, Pipaon C. Elevated levels of IL-1beta in Fanconi anaemia group A patients due to a constitutively active phosphoinositide 3-kinase-Akt pathway are capable of promoting tumour cell proliferation. Biochem J. 2009;422(1):161-170.
33. Gruber JJ, Zatechka DS, Sabin LR, et al. Ars2 links the nuclear cap-binding complex to RNA interference and cell proliferation. Cell. 2009;138(2):328-339.
34. Tili E, Michaille JJ, Cimino A, et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol. 2007;179(8):5082-5089.
35. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med. 1997;336(19):1365-1372. (Pubitemid 27208621)
36. Schultz JC, Shahidi NT. Tumor necrosis factor-alpha overproduction in Fanconi's anemia. Am J Hematol. 1993;42(2):196-201. (Pubitemid 23062174)
37. Rosselli F, Sanceau J, Gluckman E, Wietzerbin J, Moustacchi E. Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia. II. In vitro and in vivo spontaneous over-production of tumor necrosis factor alpha. Blood. 1994;83(5):1216-1225. (Pubitemid 24062844)
38. Vanderwerf SM, Svahn J, Olson S, et al. TLR8-dependent TNF-(alpha) overexpression in Fanconi anemia group C cells. Blood. 2009;114(26):5290-5298.
39. Jacome A, Navarro S, Casado JA, et al. A simplified approach to improve the efficiency and safety of ex vivo hematopoietic gene therapy in fanconi anemia patients. Hum Gene Ther. 2006;17(2):245-250. (Pubitemid 43262039)
40. Haneline LS, Broxmeyer HE, Cooper S, et al. Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from Fac-/- mice. Blood. 1998;91(11):4092-4098. (Pubitemid 28261970)
41. Otsuki T, Nagakura S,Wang J, Bloom M, Grompe M, Liu JM. Tumor necrosis factor-alpha and CD95 ligation suppress erythropoiesis in Fanconi anemia C gene knockout mice. J Cell Physiol. 1999;179(1):79-86. (Pubitemid 29108928)
42. Rathbun RK, Christianson TA, Faulkner GR, et al. Interferon-gamma-induced apoptotic responses of Fanconi anemia group C hematopoietic progenitor cells involve caspase 8-dependent activation of caspase 3 family members. Blood. 2000;96(13):4204-4211.
43. Zhang X, Li J, Sejas DP, Rathbun KR, Bagby GC, Pang Q. The Fanconi anemia proteins functionally interact with the protein kinase regulated by RNA (PKR). J Biol Chem. 2004;279(42):43910-43919. (Pubitemid 39390699)
44. Sejas DP, Rani R, Qiu Y, et al. Inflammatory reactive oxygen species-mediated hemopoietic suppression in Fancc-deficient mice. J Immunol. 2007;178(8):5277-5287. (Pubitemid 46595313)
45. Li X, Le Beau MM, Ciccone S, et al. Ex vivo culture of Fancc -/- stem/ progenitor cells predisposes cells to undergo apoptosis and surviving stem/progenitor cells display cytogenetic abnormalities and an increased risk of malignancy. Blood. 2005;105(9):3465-3471. (Pubitemid 40628187)
46. Li J, Sejas DP, Zhang X, et al. TNF-alpha induces leukemic clonal evolution ex vivo in Fanconi anemia group C murine stem cells. J Clin Invest. 2007;117(11):3283-3295. (Pubitemid 350096985)
47. Bader AG, Brown D, Winkler M. The promise of microRNA replacement therapy. Cancer Res. 2010;70(18):7027-7030.
48. Takeshita F, Patrawala L, Osaki M, et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther. 2010;18(1):181-187.
49. Liu C, Kelnar K, Liu B, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011;17(2):211-215.
50. Dufour C, Svahn J. Fanconi anaemia: new strategies. Bone Marrow Transplant. 2008;41 Suppl 2:S90-95.
51. Chuang JC, Jones PA. Epigenetics and microRNAs. Pediatr Res. 2007;61(5 pt 2):24R-29R.
52. Saito Y, Liang G, Egger G, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell. 2006;9(6):435-443. (Pubitemid 43832188)
53. Scott GK, Mattie MD, Berger CE, Benz SC, Benz CC. Rapid alteration of microRNA levels by histone deacetylase inhibition. Cancer Res. 2006;66(3):1277-1281. (Pubitemid 43259904)